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Background: Tiotropium is a once-daily inhaled anticholinergic maintenance treatment
with demonstrated effectiveness in chronic obstructive pulmonary disease (COPD).
Objective: To compare persistence of tiotropium-use with other inhaled respiratory drugs
in COPD in current clinical practice.
Methods: The PHARMO database includes, among others, drug-dispensing and hospital
discharge records for X2 million subjects in the Netherlands. All probable COPD-patients
were identified by new respiratory drug use (age454 years) or COPD-hospitalisations. New
users of tiotropium, ipratropium, long-acting beta-agonists (LABAs), or fixed combination
of LABA and inhaled corticosteroids (LABA+ICS), in 1998–2003, were included in the study.
Persistence was assessed quarterly during the first year of follow-up. Patients with a
proportion of days covered (PDC) X80% were considered persistent. Persistence was
analysed using generalised estimating equations model.
Results: About 37% of new users of tiotropium continued treatment for 1 year, compared
with 14% for ipratropium, 13% for LABA, and 17% for LABA+ICS. Multivariate analyses
showed that tiotropium-users were 2–3 times more persistent with their therapy than
patients using ipratropium (relative risk [RR]: 2.0; 95% confidence interval [CI]: 1.8–2.3),
LABA (RR: 2.9; 95% CI: 2.4–3.6), or LABA+ICS (RR: 2.4; 95% CI: 2.1–2.8), respectively. Sub-
analyses in patients with a prior hospitalisation for COPD showed that 1-year persistence
rates were increased for all treatments (varying from 33% for patients using LABA+ICS to
61% for patients using tiotropium), while persistence with tiotropium was again 2–3 times
higher compared with other treatments.Elsevier Ltd. All rights reserved.
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Persistence with tiotropium 1399Conclusion: Persistence with tiotropium was higher compared to other inhaled respiratory
drugs in COPD in clinical practice.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is projected
to be the third leading cause of death, and the fifth leading
cause of morbidity worldwide by 2020.1 Mortality figures,
attributable to COPD, are still on the rise, as are the costs,
directly or indirectly associated with COPD. Unfortunately,
there is no cure for COPD, and therefore, treatment is
supportive, designed to relieve patient symptoms, decrease
the number of exacerbations and to improve quality of life.1
Bronchodilators are the key elements in the pharmacologi-
cal management of COPD, the principal groups being
anticholinergics, b2-agonists (short- and long-acting), and
methylxanthines.2–4 In addition, inhaled corticosteroids
(ICS) are often used, though their role is still controver-
sial.5,6
COPD requires chronic therapy, however, by whatever
definition used, estimations of compliance or persistence
with inhaled respiratory medication are invariably poor.
Although adherence rates in clinical trials may be around
70–90%,7–9 in clinical practice, compliance and persistence
rates are in the range of 10–40%.10–12 Many factors that
influence the adherence to therapy with respiratory drugs
are directly related to patient characteristics and treatment
regimen, including the patients’ acceptance of the disease
process, knowledge about and faith in the treatment, and
complexity of treatment regimen.13,14
Until recently, ipratropium bromide was the mainstay of
inhaled anticholinergic therapy. In 2002, a new antic-
holinergic agent was introduced, tiotropium bromide. The
Netherlands was the first country to use it. Tiotropium has
two important advantages over ipratropium, namely, it has a
longer duration of action (20–24 h), allowing once-daily
dosing, and it is functionally more selective for specific
muscarinic receptors that mediate airway smooth-muscle
cell contraction.2,15–19 Tiotropium has shown superior
clinical effectiveness compared with ipratropium, and
long-acting beta-agonists (LABA).2,15–19 The enhanced clin-
ical effectiveness and the convenience of once-daily dosing
could lead to improved adherence to therapy in daily clinical
practice.
Therefore, the aim of the present study was to investigate
persistence with tiotropium compared with other broncho-
dilatory drugs in COPD patients in clinical practice.Methods
Setting
Data were obtained from the PHARMO Record Linkage
System, which includes, among other databases, the drug-
dispensing records from community pharmacies linked to
hospital discharge records of more than two million
community-dwelling inhabitants of 40 demographicallydefined areas in the Netherlands. At the time of this study,
more than one million subjects were included in the
database. For all residents, the computerised drug-dispen-
sing histories contain data concerning the dispensed drug,
type of prescriber, dispensing date, dispensed amount,
prescribed dose regimens, and the legend duration of use
(prescription length). All drugs are coded according to the
Anatomical Therapeutic Chemical (ATC) Classification. The
hospital records include detailed information concerning the
primary and secondary diagnoses, procedures, and dates of
hospital admission and discharge. All diagnoses are coded
according to the International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9–CM).COPD cohort
From the PHARMO database, we identified all probable
COPD patients in the period of 1998–2003. Probable COPD
patients were identified as patients who were above 54
years of age at their first dispensing for respiratory drugs in
the period of 1998–2003. Although the cut-off for COPD is
normally set at 40 years or older, we decided to set the cut-
off for COPD in the present study at 55 years, to be on the
safe side and to prevent misclassification by limiting the
possibility of accidentally including asthma patients in the
study. Patients with a dispensing for R03 in 1996 or 1997
were excluded to ensure that respiratory drug treatment
was started at the age of 55 or above to enhance the
probability of a person being treated for COPD instead of
asthma. Also, patients using antiallergics (antihistamines
and cromones) in the period of 1996–2003 were excluded, as
these patients most likely have asthma. In addition, patients
hospitalised with a primary or secondary diagnosis of chronic
bronchitis, emphysema, or chronic airway obstructions at
any point during the study period of 1998–2003 were
included in the cohort. Because of the clear COPD diagnosis
in these patients, less strict age criteria were applied and
patients were included in the study from the age of 40 years
onwards.
The cohort entry date was the date of the first respiratory
drug prescription or hospitalisation for COPD, whichever
occurred first. Patients with a history of registration in the
PHARMO RLS of less then 2 years were excluded. To ensure
that only patients with probable COPD entered the cohort,
patients with a hospitalisation for lung surgery, tuberculosis,
sarcoidosis, pulmonary fibrosis or pneumoconiosis in the
period of 2 years before the cohort entry date were
excluded, because these can result in COPD-like symptoms.
Additionally, patients who had a hospitalisation for asthma
in the period of 2 years before the cohort entry date were
excluded.
From the COPD cohort, patients were included in the
study cohort when their first prescription for tiotropium,
ipratropium, LABA, or a fixed combination of LABA and ICS
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on the Dutch market (October 2001). To ensure that
tiotropium was available for the patient, patients were
included in the study cohort when their first exposure to
tiotropium, ipratropium, LABA, or LABA+ICS, post-dated
December 2001. The date of first prescription was called the
start date. Only the first use of tiotropium, ipratropium,
LABA, or LABA+ICS, was analysed in the present study, and
patients were, therefore, included only once in the analysis.
Patients with a follow-up period in the PHARMO RLS of less
then 1 year after their start date were excluded from the
study cohort.
Ipratropium was chosen as a comparator because it was
the mainstay of inhalable anticholinergic therapy, used to
treat intermittent symptoms. LABA and LABA+ICS were
chosen as comparators because these drugs are both used
for maintenance treatment in COPD. LABA+ICS are only
indicated for severe to very severe COPD patients with
frequent exacerbations.4
Outcome definition
Persistence on the initial therapy was assessed based on the
proportion of days covered (PDC) technique, described by
Benner et al.20 This technique defines persistence as the
duration of time over which a patient continues to re-fill
drug prescriptions. The quantity dispensed and numbers of
days supplied from each filled prescription were used to
calculate the proportion of days on which a patient had the
drug available for a certain interval. Patients with a PDC of
at least 80% were defined as persistent users. For each
patient, persistence was determined every 3 months during
the first year of follow-up after the index-date. Persistence
on the initial therapy was determined irrespective of other
respiratory drug use.
Determinants of persistence
Potential determinants of persistence were considered
based upon clinical knowledge or previously published
persistence studies performed with other (respiratory) drugs
and included gender, age, type of prescriber, and year of
treatment-start.11,21,22 All of these potential determinants
were ascertained at the start date. In the year prior to the
start date, proxies for severity of obstructive lung diseases
were assessed as possible determinants for persistence with
tiotropium or the other selected therapies. These markers
included previous hospitalisations for obstructive lung
disease, and prior use of drugs with a labelled indication
of obstructive lung diseases, as described by other
researchers.11,21,22 Hospitalisation for obstructive lung
diseases was defined as a hospitalisation for COPD/chronic
bronchitis (ICD-9–CM: 491), emphysema (ICD-9–CM: 492), or
chronic airway obstruction (ICD-9–CM: 496).11
The use of drugs with a labelled indication of obstructive
lung diseases included short-acting beta-agonists (SABA),
LABA, ipratropium, tiotropium, xanthine-derivatives, ICS,
fixed combinations of SABA and ipratropium, or fixed
combinations of LABA and ICS. Other co-medication related
to chronic respiratory disease included cough medications,
mucolytics, nasal preparations, and oral corticosteroids.In addition, the adapted Chronic Disease Score, a chart-
based co-morbidity index based on pharmacy data,23 was
calculated excluding drugs related to asthma/COPD. Total
Chronic Disease Score was classified into class 1 (CDS 0–1),
class 2 (CDS 2–4), and class 3 (CDS44), with a higher Chronic
Disease Score indicating higher disease severity of chronic
co-morbidity.
Analysis
Baseline characteristics of users of tiotropium, ipratropium,
LABA, or LABA+ICS, were determined and frequency
distributions are presented. Univariate logistic regression
analysis was performed to estimate odds ratios and 95%
confidence intervals to compare the baseline characteristics
between users of tiotropium and the other selected
therapies.
Persistence was analysed using a logistic regression model
for binomial distributed data, in which the correlation
between data of the same patient in the course of follow-up
was taken into account (generalised estimating equations,
GEE).24 For the distances between two quarters of a year
(e.g. 3, 6, and 9 months) a separate correlation coefficient
was estimated. This resulted in a covariance structure with
minimal assumptions (unstructured). Variables potentially
associated with persistence in the crude analyses were
included in the multivariate analyses, namely: time (quar-
ter) since start of therapy, year of treatment-start, gender,
age, prescriber, previous drugs used for COPD, prior
co-medication related to COPD, previous hospitalisations,
and Chronic Disease Score. Statistical significance was
defined at an alpha level of 0.05.
Sub-analyses were performed comparing persistence in
time and differences between treatment groups in patients
with a prior hospitalisation for COPD.
All data were analysed using SAS programs organized
within SAS Enterprise Guide version 3.0 (SAS Institute
Inc., Cary, NC, USA) and conducted under UNIX using SAS
version 9.1.
Results
A total of 5330 patients met the inclusion criteria of our
study. Of these patients, 1028 were new users of tiotropium,
1722 of ipratropium, 554 of LABA, and 2026 were new users
of LABA+ICS combination therapy. Patient characteristics
are presented in Table 1. Compared with the other selected
therapies, tiotropium was more frequently prescribed to
male patients, by a pulmonologist, and in the year 2003. In
the year prior to treatment-initiation, tiotropium users
more frequently had been prescribed other respiratory drugs
(such as xanthine derivatives and ICS) compared with new
users of ipratropium, LABA, or LABA+ICS. The differences
were most pronounced for tiotropium compared with
ipratropium. In addition, tiotropium users more frequently
had used mucolytics, nasal preparations, oral corticoster-
oids, and oral antibiotics in the year prior to therapy-start
compared with patients starting one of the other three
therapies. Furthermore, new users of tiotropium had been
hospitalised more frequently in the year prior to starting
tiotropium, both for COPD, and for other reasons, and had
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Table 1 Patient characteristics at baseline for users of tiotropium, ipratropium, LABA, and LABA+ICS
Characteristic Tiotropium (N ¼ 1028)
(ref.)
Ipratropium
(N ¼ 1722)
LABA (N ¼ 554) LABA+ICS (N ¼ 2026)
n % n % n % n %
At index-date
Gender
Female (ref.) 429 41.7 854 49.6 300 54.2 1010 49.9
Male 599 58.3 868 50.4 254 45.8 1016 50.1
Age group (in yrs)
40–49 11 1.1 3 0.2 4 0.7 29 1.4
50–59 116 11.3 213 12.4 72 13.0 297 14.7
60–69 (ref.) 323 31.4 495 28.7 181 32.7 737 36.4
70–79 396 38.5 664 38.6 204 36.8 693 34.2
479 182 17.7 347 20.2 93 16.8 270 13.3
Prescriber
General practitioner
(ref.)
505 49.1 1375 79.8 381 68.8 1203 59.4
Pulmonologist 523 50.9 347 20.2 173 31.2 823 40.6
Year of start
2002 (ref.) 550 53.5 1213 70.4 349 63.0 1201 59.3
2003 478 46.5 509 29.6 205 37.0 825 40.7
One year prior to index-date
Respiratory drugs
SABA 239 23.2 187 10.9 142 25.6 455 22.5
LABA 253 24.6 44 2.6 — — 312 15.4
Ipratropium 446 43.4 — — 98 17.7 379 18.7
Tiotropium — — 2 0.1 4 0.7 10 0.5
Xanthine derivatives 121 11.8 12 0.7 11 2.0 91 4.5
ICS 368 35.8 164 9.5 150 27.1 626 30.9
SABA + ipratropium 115 11.2 20 1.2 24 4.3 120 5.9
LABA+ICS 237 23.1 51 3.0 25 4.5 – –
Co-medication related to COPD
Coughing agents 120 11.7 277 16.1 71 12.8 298 14.7
Mucolytics 236 23.0 121 7.0 59 10.6 240 11.8
Nasal preparations 181 17.6 175 10.2 54 9.7 251 12.4
Oral corticosteroids 394 39.3 228 13.2 134 24.2 574 28.3
Oral antibiotics 623 60.6 830 48.2 284 51.3 1152 56.9
Hospitalisation for COPD 126 12.3 38 2.2 34 6.1 161 7.9
CDS
0–1 (ref.) 341 33.2 688 40.0 228 41.4 826 40.8
2–4 300 29.2 483 28.0 153 27.6 604 29.8
44 387 37.6 551 32.0 173 31.2 596 29.4
Significantly different from tiotropium users by univariate logistic regression analysis (Po0.05). COPD: chronic obstructive
pulmonary disease; ICS: inhaled corticosteroids; LABA: long-acting beta-agonists; ref.: reference category; SABA: short-acting beta-
agonists; CDS: chronic disease score.
Persistence with tiotropium 1401higher Chronic Disease Scores compared with new users of
ipratropium, LABA, or LABA+ICS.
About 37% of new users of tiotropium continued treat-
ment for 1 year, compared with 14% of new users of
ipratropium, 13% of new users of LABA, and 17% of new users
of LABA+ICS.
The mean PDC for each time-interval in the first year of
treatment is shown in Fig. 1. Mean PDC was highest fortiotropium during each time-interval, while persistence
decreased with time since start of therapy, persistence
being highest for the first quarter after start of therapy, and
the lowest for the fourth quarter after start of therapy. A
sub-analysis of all patients with a prior hospitalisation for
COPD showed that these patients had higher 1-year
persistence rates. About 61% of new users of tiotropium
continued treatment for 1 year compared with 37% of new
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Figure 1 Mean proportion of days covered by tiotropium, ipratropium, LABA, and LABA+ICS, for each time-interval in the first year
of treatment with each therapy in COPD patients. COPD ¼ chronic obstructive pulmonary disease; LABA+ICS ¼ long-acting beta-
agonists and inhaled corticosteroids; M ¼ months; LABA ¼ long-acting beta-agonists.
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Figure 2 Mean proportion of days covered by tiotropium, ipratropium, LABA, and LABA+ICS, for each time-interval in the first year
of treatment with each therapy in COPD patients with a prior hospitalisation for COPD. COPD ¼ chronic obstructive pulmonary
disease; LABA+ICS ¼ long-acting beta-agonists and inhaled corticosteroids.
N.S. Breekveldt-Postma et al.1402users of ipratropium, 41% of new users of LABA, and 33% of
new users of LABA+ICS. Mean PDC was higher with
tiotropium than with ipratropium, LABA, or LABA+ICS in
the second and third quarter after start of therapy, while
differences were less clearly observed in the fourth quarter
after start as shown in Fig. 2.
Multivariate analyses, including all determinants that
were associated with persistence in the crude analyses,
showed that there were still significantly differences in 1-
year persistence between treatment groups (Table 2). Users
of ipratropium, LABA or LABA+ICS all had a lower chance
(RRo1) of being persistent with their drug than users of
tiotropium, independently of other factors like type of
prescriber, use of other respiratory drugs and hospitalisationfor COPD. From the perspective of tiotropium, persistence
with tiotropium was twice as high as with ipratropium
(RR: 2.04; 95% CI: 1.75–2.33), or LABA+ICS (RR: 2.44; 95%
CI: 2.13–2.78), and three times higher compared with LABA
(RR: 2.94; 95% CI: 2.44–3.57). Other determinants that were
associated with higher persistence rates were, in relative
order of highest relative risk (RR), a pulmonologist as
first prescriber, prior use of other respiratory drugs (in
particular prior use of ICS, oral corticosteroids, or SABA),
age older than 70 years, male gender, and a previous
hospitalisation related to COPD in the 1-year period prior to
the start date. On the other hand, persistence rates
decreased for patients starting their therapy in 2003
compared with 2002.
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Table 2 Determinants of one-year persistence for treatment with tiotropium, ipratropium, LABA, and LABA+ICS in COPD
patients
Determinant Crude Adjusteda
RR 95% CI RR 95% CI
At index-date
Treatment for COPD
Tiotropium 1.0 (ref.) — 1.0 (ref.) —
Ipratropium 0.33 0.29–0.38 0.49 0.43–0.57
LABA 0.28 0.23–0.34 0.34 0.28–0.41
LABA+ICS 0.37 0.32–0.42 0.41 0.36–0.47
Time (quarter since start of therapy)
First quarter 4.41 4.08–4.76 5.25 4.82–5.71
Second quarter 1.86 1.73–2.00 2.00 1.85–2.16
Third quarter 1.32 1.23–1.41 1.36 1.26–1.46
Fourth quarter 1.0 (ref.) — 1.0 (ref.) –
Year of start
2002 1.0 (ref.) — 1.0 (ref.) —
2003 0.80 0.73–0.89 0.80 0.72–0.88
Gender
Female 1.0 (ref.) — 1.0 (ref.) —
Male 1.32 1.20–1.45 1.23 1.11–1.35
Age group (in yrs)
40–49 2.08 1.26–3.43 1.07 0.63–1.82
50–59 0.98 0.83–1.15 0.95 0.81–1.12
60–69 1.0 (ref.) — 1.0 (ref.) —
70–79 1.22 1.09–1.37 1.19 1.06–1.34
479 1.23 1.07–1.42 1.38 1.19–1.60
Prescriber
General practitioner 1.0 (ref.) — 1.0 (ref.) —
Pulmonologist 2.60 2.36–2.87 1.95 1.74–2.17
One year prior to index-date
Respiratory drugs
SABA 1.88 1.67–2.11 1.29 1.13–1.48
ICS 2.45 2.20–2.73 1.60 1.41–1.81
Theophyllineb 3.39 2.74–4.19 1.23 0.97–1.56
Co-medication related to COPD
Oral corticosteroids 2.19 1.97–2.44 1.36 1.20–1.54
Oral antibiotics 1.23 1.12–1.35 0.94 0.85–1.04
Prior hospitalisations
None 1.0 (ref.) — 1.0 (ref.) —
Not related to COPD 1.23 1.11–1.38 0.93 0.83–1.05
Related to COPD 3.02 2.55–3.59 1.22 0.99–1.49
CDS
0–1 1.0 (ref.) — 1.0 (ref.) —
2–4 1.14 1.01–1.29 1.01 0.90–1.15
44 1.23 1.10–1.38 0.98 0.87–1.11
CI: (95%) confidence interval; COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroids; LABA: long-acting beta-
agonists; RR: relative risk; ref.: reference category; SABA: short-acting beta-agonists; CDS: chronic disease score.
Significantly different (Po0.05).
aEach factor in the model was adjusted for the other factors in the table.
bMost frequently present xanthine derivative.
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COPD also showed that persistence with tiotropium was two
to three times increased compared with ipratropium (RR:
2.27; 95% CI: 1.35–3.85), LABA+ICS (RR: 2.08; 95% CI:
1.11–3.85), and LABA (RR: 2.78; 95% CI: 1.96–4.00).Discussion
The results of the present population-based cohort study
show that COPD patients using tiotropium were two to three
times more persistent with their therapy than COPD patients
using ipratropium, LABA, or LABA+ICS after 1 year, when
adjusted for differences in patient characteristics. Overall,
about 37% of patients using tiotropium were persistent with
their initial therapy during the first year compared with
13–17% of patients using one of the other therapies. In a sub-
cohort of patients with a prior hospitalisation for COPD,
about 61% of new users of tiotropium were persistent with
their initial therapy during the first year compared with
33–41% of patients using one of the other therapies.
To our knowledge, this is one of the first daily practice-
based studies on (1-year) persistence with tiotropium in
patients with COPD. The observed persistence rates are in
line with persistence and compliance rates with respiratory
drugs observed in other studies. Most studies performed
report compliance rates with inhaled respiratory drugs that
can be as low as 20%, with higher adherence rates up to
70–90% observed in clinical trials. Low adherence or
compliance may also be one of the most important
explanatory factors of non-persistence in the present study.
Major reasons for non-adherence are patient’s interpreta-
tion of their disease and treatment and complexity of the
treatment regimen and administration (inhalation).13,14,25
Simplification of dosing regimens by reducing dose frequen-
cies has been shown to increase medication adherence in
several chronic diseases.25 Therefore, once-daily dosing of
tiotropium compared with LABA and LABA+ICS which are
mostly dosed twice-daily and ipratropium which is dosed
three to four times daily, may lead to enhanced persistence.
Also, the sustained bronchodilatation for 24 h and possibly
superior clinical effectiveness, may favourably contribute to
an improved persistence with tiotropium.2–4,18,19,26–30
There are other factors that may determine non-
persistence, one of those being the doctor’s decision to
change type of treatment. In case of ipratropium which is
used to treat intermittent symptoms, it is common that
patients change from intermittent treatment to mainte-
nance treatment. The present study indicates, however,
that although ipratropium is used to treat intermittent
symptoms, it is also used daily/persistently. In case of
tiotropium, LABA and LABA+ICS which are maintenance
treatments, it is less likely that patients switch treatment
except for reasons of inefficacy. As mentioned before,
superior clinical effectiveness of tiotropium may explain the
increased persistence rates.
Comparing adjusted relative risks with crude relative risks
shows that part of the difference in persistence between
tiotropium and the other therapies is explained by differ-
ences in patient characteristics. New users of tiotropium
more often received their first prescription from the
specialist, had already used other respiratory drugs, andmore often had a hospitalisation for COPD in the year prior
to the start of their therapy. These factors may be indicative
of a higher disease severity, which has been associated with
increased persistence as we have shown previously.11
One reason that may partly explain the observed
differences in patient characteristics, is the doctor’s
preference to prescribe new drugs to patients who do not
respond adequately to earlier approved drugs or who do not
tolerate these drugs.31 During the first few years of
marketing, newly introduced drugs have to compete with
older drugs with greater patient experience. In general, it is
reasonable to expect that prescribers do not switch patients
to new drugs if patients are responding satisfactorily and
maintaining good tolerability to earlier approved drugs. This
is a common cause of selection bias when comparing the
efficacy and safety of drugs in clinical practice. Although we
adjusted for various covariates to control this type of
selection bias, we cannot rule out the possibility that other
factors for which we did not have information, may have
confounded our findings.
To control for differences in indication of use a sub-
analysis of persistence was performed in patients with a
prior hospitalisation for COPD. It may be expected that
these patients are more comparable with regard to disease
severity and/or awareness of their disease. These patients
generally had higher persistence rates and persistence with
tiotropium was still increased compared with the other
respiratory drugs. These results confirm that the higher
persistence with tiotropium is only partly explained by
differences in disease severity.
Selection of COPD-patients for the current study was
based on respiratory drug use or hospitalisations for COPD.
By applying various exclusion criteria, such as age at onset
of respiratory drug use and prior use of asthma-specific
drugs, as many asthma patients as possible were excluded.
However, we cannot exclude that some patients treated for
asthma were included in the study cohort. As tiotropium is
indicated for COPD and not for asthma, in contrast to LABA
and LABA+ICS, this may have resulted in a mixed asthma–
COPD patient population for the other therapies.
Part of the observed differences in persistence therefore
may be explained by differences in treatment of asthma and
COPD patients. As mentioned before, to rule out possible
differences in diagnosis, we performed a sub-analysis in
patients with a prior hospitalisation for COPD. Also in this
population, persistence with tiotropium was increased twice
compared to the other drugs used, although differences
were less at the end of the study period. These results
clearly show that differences between treatment groups
cannot be explained by differences in diagnosis.
Although the observed quantitative persistence rates in
the present study may not be representative for the entire
COPD population, the study clearly showed that persistence
with tiotropium is increased compared to other mainte-
nance treatments in COPD. Future research including a focus
on symptom relief and tolerability is warranted to under-
stand the reasons for the higher persistence levels with
tiotropium.
In conclusion, in the present large population-based
cohort study among COPD patients, 1-year persistence with
tiotropium is higher compared to both ipratropium and the
maintenance treatments LABA and LABA+ICS.
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